Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Mar 6

PMID 33670761

Citations 12

Authors

Carsten Grundker

Gunter Emons

Affiliations

Soon will be listed here.

Abstract

The hypothalamus-pituitary-gonadal (HPG) axis is the endocrine regulation system that controls the woman's cycle. The gonadotropin-releasing hormone (GnRH) plays the central role. In addition to the gonadotrophic cells of the pituitary, GnRH receptors are expressed in other reproductive organs, such as the ovary and in tumors originating from the ovary. In ovarian cancer, GnRH is involved in the regulation of proliferation and metastasis. The effects on ovarian tumors can be indirect or direct. GnRH acts indirectly via the HPG axis and directly via GnRH receptors on the surface of ovarian cancer cells. In this systematic review, we will give an overview of the role of GnRH in ovarian cancer development, progression and therapy.

Citing Articles

Oxidative Stress-Related KEAP1 and NRF2 Genes Contributed to the Risk of Epithelial Ovarian Cancer.

Tong X, Zhu X, Wang X, Xu Y, Huang P, Zhou L Biochem Genet. 2025; .

PMID: 39945964 DOI: 10.1007/s10528-025-11044-z.

GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.

Patel S, Saxena B, Mehta P, Niazi S Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861098 PMC: 11768417. DOI: 10.3390/ph18010036.

Targeted lipidomics analysis of possible molecular mechanisms of lipid changes in temporal lobe epilepsy models.

Sun H, Li X, Chen Z, Meng H Front Pharmacol. 2025; 15():1531524.

PMID: 39850562 PMC: 11754250. DOI: 10.3389/fphar.2024.1531524.

Association between ovarian tumors and exposure to assisted reproductive technologies and ovarian stimulation: a systematic review and meta-analysis.

Lobo A, Morbach V, Kelly F, de Moraes F Arch Gynecol Obstet. 2024; 310(6):2753-2765.

PMID: 39412534 DOI: 10.1007/s00404-024-07763-0.

Cytotoxic Activity of Novel GnRH Analogs Conjugated with Mitoxantrone in Ovarian Cancer Cells.

Markatos C, Biniari G, Chepurny O, Karageorgos V, Tsakalakis N, Komontachakis G Molecules. 2024; 29(17.

PMID: 39274973 PMC: 11397358. DOI: 10.3390/molecules29174127.

References

Keri G, Balogh A, Szoke B, Teplan I, Csuka O . Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell line. Tumour Biol. 1991; 12(2):61-7. View

Harris N, Dutlow C, Eidne K, Dong K, Roberts J, Millar R . Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Res. 1991; 51(10):2577-81. View

McArdle C, Franklin J, Green L, Hislop J . Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol. 2002; 173(1):1-11. DOI: 10.1677/joe.0.1730001. View

Millar R . GnRH II and type II GnRH receptors. Trends Endocrinol Metab. 2002; 14(1):35-43. DOI: 10.1016/s1043-2760(02)00016-4. View

Grundker C, Huschmand Nia A, Emons G . Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers. Mol Cancer Ther. 2005; 4(2):225-31. View

Millar R, Newton C . Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol. 2013; 9(8):451-66. DOI: 10.1038/nrendo.2013.120. View

Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser H . Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol. 2000; 17(5):1063-9. DOI: 10.3892/ijo.17.5.1063. View

Ron I, Wigler N, Merimsky O, Inbar M, Chaitchik S . A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer. Cancer Invest. 1995; 13(3):272-5. DOI: 10.3109/07357909509094461. View

Neill J, Duck L, Sellers J, Musgrove L . A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochem Biophys Res Commun. 2001; 282(4):1012-8. DOI: 10.1006/bbrc.2001.4678. View

10.

Gunthert A, Grundker C, Bottcher B, Emons G . Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells. Anticancer Res. 2004; 24(3a):1727-32. View

11.

Perets R, Drapkin R . It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. Cancer Res. 2015; 76(1):10-7. PMC: 4703449. DOI: 10.1158/0008-5472.CAN-15-1382. View

12.

Langdon S, Hirst G, Miller E, Hawkins R, Tesdale A, Smyth J . The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol. 1994; 50(3-4):131-5. DOI: 10.1016/0960-0760(94)90019-1. View

13.

Emons G, Schroder B, Ortmann O, Westphalen S, Schulz K, Schally A . High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab. 1993; 77(6):1458-64. DOI: 10.1210/jcem.77.6.8263128. View

14.

Keizer J, Li Y, STOJILKOVIC S, Rinzel J . InsP3-induced Ca2+ excitability of the endoplasmic reticulum. Mol Biol Cell. 1995; 6(8):945-51. PMC: 301254. DOI: 10.1091/mbc.6.8.945. View

15.

Fuseya T, Imai A, Horibe S, Takagi A, Tamaya T . Evidence for common signalling pathways of GnRH receptor and Fas in tumors. Oncol Rep. 2011; 3(6):1111-3. DOI: 10.3892/or.3.6.1111. View

16.

Bonfil D, Chuderland D, Kraus S, Shahbazian D, Friedberg I, Seger R . Extracellular signal-regulated kinase, Jun N-terminal kinase, p38, and c-Src are involved in gonadotropin-releasing hormone-stimulated activity of the glycoprotein hormone follicle-stimulating hormone beta-subunit promoter. Endocrinology. 2004; 145(5):2228-44. DOI: 10.1210/en.2003-1418. View

17.

Olbrich T, Ziegler E, Turk G, Schubert A, Emons G, Grundker C . Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: Evidence for a dose-window effect. Gynecol Oncol. 2010; 119(3):571-8. DOI: 10.1016/j.ygyno.2010.08.018. View

18.

Moretti R, Marelli M, Dondi D, Poletti A, Martini L, Motta M . Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab. 1996; 81(11):3930-7. DOI: 10.1210/jcem.81.11.8923840. View

19.

Neill J, Musgrove L, Duck L . Newly recognized GnRH receptors: function and relative role. Trends Endocrinol Metab. 2004; 15(8):383-92. DOI: 10.1016/j.tem.2004.08.005. View

20.

Parmar H, Rustin G, Lightman S, Phillips R, Hanham I, Schally A . Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. Br Med J (Clin Res Ed). 1988; 296(6631):1229. PMC: 2545706. DOI: 10.1136/bmj.296.6631.1229. View